Preventing Alzheimer's With Cognitive Training

NCT ID: NCT03848312

Last Updated: 2024-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

7600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-19

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residential care needs) and indirect (e.g., lost productivity of family caregivers) economic costs. Implementing interventions to prevent MCI and dementia among older adults is of critical importance to health and maintained quality-of-life for millions of Americans. Recent data analyses from the Advanced Cognitive Training in Vital Elderly study (ACTIVE) indicate that a specific cognitive intervention, speed of processing training (SPT), significantly delays the incidence of cognitive impairment across 10 years. The primary contribution of the proposed research will be the determination of whether this cognitive training technique successfully delays the onset of clinically defined MCI or dementia across three years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preventing Alzheimer's Disease with Cognitive Training: The PACT Trial

The primary objective in the R56 phase was to establish the feasibility of the proposed field trial including meeting participant enrollment goals. The feasibility of the field trial was established by accruing 1000 enrolled participants. The secondary objective in the R56 phase was to ascertain participants' willingness to enroll in a longitudinal clinical trial and to subsequently complete a multispecialty clinical diagnostic evaluation, psychometric testing, MRI, PET scan, and genetic testing. Participants' willingness to allow access to medicare records was also determined.

The trial is being expanded in the R01 phase with the goal of enrolling 7600 participants.

The primary goal is to ascertain the effectiveness of cognitive speed of processing training (SPT) to reduce the incidence of Mild Cognitive Impairment (MCI) or dementia.

Design and Outcomes: A randomized clinical trial among 7600 adults 65 years of age and older will be completed in order to test the effectiveness of computerized cognitive speed of processing training (SPT) to reduce incidence of MCI or dementia.

Participants will be screened with an inclusion/exclusion questionnaire and those potentially eligible will complete brief memory screening, depression screening, and other questionnaires. Those eligible will be randomized to one of two conditions of brain games and will complete at least two in-person, supervised training sessions. Additional exercises will be completed at-home over the next 3 to 5 months followed by booster sessions 1- and 2-years later.

Participants are asked to initially complete 25 sessions of training and will be asked complete an additional 10 sessions of booster training 1- and 2- years later. Participants are instructed to complete 2-3 sessions of training per week until 25 sessions are completed. At 1- year and again at 2-years, participants will be instructed to complete an additional 10 sessions of training.

Sample Size and Population: Adults 65 years of age and older (N=7600) will be randomly assigned to SPT (n=3800) or the active comparator condition (n=3800).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-related Cognitive Decline Alzheimer's Disease and Related Dementias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Computerized Cognitive Training

Participants will complete computerized cognitive training.

Group Type EXPERIMENTAL

Cognitive Training

Intervention Type BEHAVIORAL

Participants will be completing a total of 45 computerized sessions.

Computerized Cognitive Stimulation

Participants will complete cognitively-stimulating computer activities.

Group Type ACTIVE_COMPARATOR

Computerized Cognitive Stimulation

Intervention Type BEHAVIORAL

Participants will be completing a total of 45 computerized cognitive stimulation sessions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cognitive Training

Participants will be completing a total of 45 computerized sessions.

Intervention Type BEHAVIORAL

Computerized Cognitive Stimulation

Participants will be completing a total of 45 computerized cognitive stimulation sessions.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be age 65 or older at time of consent
* Have ability to speak and understand English or Spanish
* Report adequate sensorimotor capacity to perform the computer exercises
* Report adequate visual capacity to read from a computer screen at a typical viewing distance
* Show adequate auditory capacity to understand conversational speech
* Show adequate motor capacity to touch a computer screen or control a computer mouse.
* Have no evidence of Mild Cognitive Impairment (MCI) or dementia, as assessed by the Montreal Cognitive Assessment score \>=26.
* Have adequate mental health (no self-reported diagnoses of mental illness that would interfere with ability to comply with study procedures or benefit from intervention)
* Wiling to complete all study activities
* Ability to understand study procedures and comply with them for the length of the study

Exclusion Criteria

* Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition
* Previous participation in a cognitive training study
* Self-reported vision, hearing, or motor difficulties that would interfere with the ability to complete the study interventions
* Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic brain injury, brain tumor, or a neurological disorder that affects cognition or would interfere with the ability to benefit from the study intervention (e.g., Parkinson disease, multiple sclerosis), or any other unstable medical conditions that is predisposing to imminent cognitive or functional decline (e.g., congestive heart failure, chronic obstructive pulmonary disorder dependent on oxygen, or undergoing chemotherapy or radiation).
* Self-reported use of medications typically prescribed for dementia such as: Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, aducanumab, Aduhlem.
* Completion of 10 or more hours of a computerized cognitive training program in the last 5 years such as: Lumosity, Posit Science Brain Fitness, InSight, or Brain HQ, Lace, CogMed, CogniFit, Happy Neuron, Elevate, or Dakim
* Severe depressive symptoms (Geriatric Depression Scale score \>=5)
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

University of South Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jennifer L. O'Brien

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida

Gainesville, Florida, United States

Site Status ACTIVE_NOT_RECRUITING

University of Florida

Jacksonville, Florida, United States

Site Status ACTIVE_NOT_RECRUITING

University of North Florida

Jacksonville, Florida, United States

Site Status TERMINATED

The Roskamp Institute

Sarasota, Florida, United States

Site Status RECRUITING

University of South Florida

Tampa, Florida, United States

Site Status RECRUITING

Duke Health

Durham, North Carolina, United States

Site Status RECRUITING

Clemson University Institute for Engaged Aging

Seneca, South Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jennifer L O'Brien, PhD

Role: CONTACT

727-873-4415

Jennifer Lister, PhD

Role: CONTACT

813-974-9712

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dorothy St. Pierre

Role: primary

941-500-4447

Hope Clark-Bell

Role: primary

813-974-6703

Marianne Chanti-Ketterl, PhD

Role: primary

919-668-3154

Kimberly Scoles

Role: primary

864-916-6220

References

Explore related publications, articles, or registry entries linked to this study.

Nicholson JS, Hudak EM, Phillips CB, Chanti-Ketterl M, O'Brien JL, Ross LA, Lister JJ, Burke JR, Potter G, Plassman BL, Woods AJ, Krischer J, Edwards JD. The Preventing Alzheimer's with Cognitive Training (PACT) randomized clinical trial. Contemp Clin Trials. 2022 Dec;123:106978. doi: 10.1016/j.cct.2022.106978. Epub 2022 Oct 28.

Reference Type DERIVED
PMID: 36341846 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R56AG058234-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R01AG070349-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

WIRB® Protocol #20182630

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Caring for the Caregiver Network
NCT03049501 COMPLETED NA